Publications, Pharmaceutical

Demonstrating bioequivalence for generic fluticasone propionate OINDPs

Optimal strategies for demonstrating bioequivalence for commonly used inhaled drugs are highly relevant to the cost-effective development of generics.

This paper considers the use of pharmacokinetics in the demonstration of the bioequivalence of fluticasone propionate inhalation products, without the need for comparative clinical endpoint studies. Compartmental and non-compartmental pharmacokinetic analyses for three alternative fluticasone dry powder inhaler formulations are examined. These data showed good agreement with formulation characteristics measured using in vitro methods and highlight the potential to use pharmacokinetic studies to assess the dose accessible to the lungs, regional deposition, and pulmonary residence time. The work illustrates how batch-to-batch differences in adjuvant or excipient properties influence pharmacokinetics, providing helpful guidance for those developing generic products.

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top